Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients

Pharmacogenomics

Volumn 8, Issue 2, 2007, Pages 141-150

  van der Straaten, R J H M ^a   Wessels, Judith A M ^a   de Vries Bouwstra, Jeska K ^b   Goekoop Ruiterman, Yvonne P M ^a   Allaart, Cornelia F ^a   Bogaartz, Judith ^a   Tiller, Marco ^a   Huizinga, Tom W J ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

glutamyl hydrolase; Folylpoly glutamate synthase; Methotrexate; Pyrosequencing; Rheumatoid arthritis; Single nucleotide polymorphisms

Indexed keywords

ADENINE; AMINO ACID; CYTOSINE; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; GAMMA GLUTAMYL HYDROLASE; GUANINE; METHOTREXATE; THYMIDINE;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSAL DISEASE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; GAMMA-GLUTAMYL HYDROLASE; GENE FREQUENCY; HUMANS; METHOTREXATE; PEPTIDE SYNTHASES; POLYMORPHISM, SINGLE NUCLEOTIDE; SINGLE-BLIND METHOD;

EID: 33847075831     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.2.141     Document Type: Article

References (42)

1. Weinblatt ME, Coblyn JS, Fox DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312, 818-822 (1985).
2. Kremer JM, Lee JK: The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 29, 822-831 (1986).
3. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol. 21, S179-S185 (2003).
4. Aletaha D, Smolen JS: The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 41, 1367-1374 (2002).
5. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 39, 975-981 (2000).
6. Dervieux T, Furst D, Lein DO et al.: Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann. Rheum. Dis. 64, 1180-1185 (2005).
7. Masson E, Relling MV, Synold TW et al.: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J. Clin. Invest. 97, 73-80 (1996).
8. Whitehead VM, Rosenblatt DS, Vuchich NU, Shuster JJ, Witte A, Beaulieu D: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 76, 44-49 (1990).
9. Galivan J, Ryan T, Rhee M, Yao R, Chave K: Glutamyl hydrolase: properties and pharmacologic impact. Semin Oncol. 26, 33-37 (1999).
10. Rhee MS, Lindau-Shepard B, Chave KJ, Galivan J, Ryan TJ: Characterization of human cellular γ-glutamyl hydrolase. Mol. Pharmacol. 53, 1040-1046 (1998).
11. Panetta JC, Wall A, Pui CH, Relling MV, Evans WE: Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of γ-glutamyl hydrolase activity. Clin. Cancer Res. 8, 2423-2429(2002).
12. Longo GS, Gorlick R, Tong WP, Lin S, Steinherz P, Bertino JR: γ-Glutamyl hydrolase and folypolyglutamate synthase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol. Res. 9, 259-263 (1997).
13. Dervieux T, Furst D, Lein DO et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50, 2766-2774 (2004).
14. Urano W, Taniguchi A, Yamanaka H et al.: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12, 183-190 (2002).
15. Wessels JA, Vries-Bouwstra JK, Heijmans BT et al.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54, 1087-1095 (2006).
16. Chave KJ, Ryan TJ, Chmura SE, Galivan J: Identification of single nucleotide polymorphisms in the human γ-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene 319, 1167-175 (2003).
17. Dervieux T, Kremer J, Lein DO et al.: Contribution of common polymorphisms; in reduced folate carrier and γ-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogeneticss 14, 733-739 (2004).
18. Cheng Q. Wu B, Kager L et al.: A substrate specific functional polymorphism of human γ-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics 14, 557-567 (2004).
19. Angelis-Stoforidis P, Vajda FJ, Christophidis N: Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol. 17, 313-320 (1999).
20. Aghi M, Kramm CM, Breakefield XO: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J. Natl Cancer Inst. 91, 1233-1241 (1999).
21. Odin E, Wettergren Y, Nilsson S et al.: Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin. Cancer Res. 9, 6012-6019 (2003).
22. Wettergren Y, Odin E, Nilsson S, Willen R, Carlsson G, Gustavsson B: Low expression of reduced folate carrier-1 and folylpolyglutamate synthase correlates with lack of a deleted in colorectal carcinoma mRNA splice variant in normal-appearing mucosa of colorectal carcinoma patients. Cancer Detect. Prev. 29, 348-355 (2005).
23. Stranzl T, Wolf J, Leeb BF, Smolen JS, Pirker R, Filipits M: Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 21, 27-32 (2003).
24. Goekoop-Ruiterinan YP, Vries-Bouwstra JK, Allaart CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381-3390 (2005).
25. Arnett FC, Edworthy SM, Bloch DA et al.: The American Rheumatism Association (1987) revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31. 315-324 (1988).
26. van Gestel AM, Prevoo, ML, 'tHof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 39, 34-40 (1996).
27. van der Heijde DM, van 't HM, van Riel PL, van de Putte LB: Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J. Rheumatol. 20, 538-541 (1993).
28. Westendorp RG, Langermans JA, Huizinga TW et al.: Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349, 170-173 (1997).
29. Rood MJ, van Krugten MV, Zanelli E et al.: TNF-308A, HLA-DR3 andes contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 43, 129-134 (2000).
30. van der Heijde DM, van't HM, van Riel PL, van de Putte LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 20, 579-581 (1993).
31. Huizinga TW, Pisetsky DS, Kimberly RP: Associations, populations, and the truth: recommendations for genetic association studies in arthritis and rheumatism. Arthritis Rheum. 50, 2066-2071 (2004).
32. Newton-Cheh C, Hirschhorn JN: Genetic association studies of complex traits: design and analysis issues. Mutat. Res. 573, 54-69 (2005).
33. Cheng Q, Cheng C, Crews KR et al.: Epigenetic regulation of human γ-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am. J. Hum. Genet. 79, 264-274 (2006).
34. Hughes LB, Beasley TM, Patel H et al.: Racial or ethr-dc differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65, 1213-1218 (2006).
35. Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG: Loss of folyipoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int. J. Cancer 103, 587-599 (2003).
36. Kager L, Cheok M, Yang W et al.: Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J. Clin. Invest. 115, 110-117 (2005).
37. Barredo JC, Synold IV, Laver J et al.: Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84, 564-569 (1994)
38. Barredo J, Moran RG: Determinants of antifolate cytotoxicity: folylpolyglutamate synthetase activity during cellular proliferation and development. Mol. Pharmacol. 42, 687-694 (1992).
39. Whitehead VM, Vuchich MJ, Lauer SJ et al.: Accumulation of high Levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid Weater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 80, 1316-1323 (1992).
40. Galpin AJ, Schuetz JD, Masson E et al.: Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol. Pharmacol. 52, 155-163 (1997).
41. Leclerc GJ, Barredo JC: Folyipoly- γ-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell fines, and normal human tissues. Clin. Cancer Res. 7, 942-951 (2001).
42. Leclerc GJ, Leclerc GM, Kinser TT, Barredo JC: Analysis of folyipoly-γ-glutamate synthetase gene expression in human B-precursor ALL, T-Uneage ALL cells. BMC Cancer 6, 132 (2006).